← Russell 3000 cross-section

OMCL OMNICELL, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Technology

Scale

Market cap
$1.5bn
Revenue TTM
$1.2bn
Net income TTM
$39m
Free cash flow
$143m
Composite score
66.0
Sector rank
#1780

Valuation

P / E
39.1
EV / EBITDA
9.2
EV / sales
1.0
FCF yield
9.33%
Earnings yield vs 10-yr
-2.17pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
3.1%
EBITDA margin
10.8%
ROE
3.0%
ROIC
5.8%
Revenue growth
8.4%

Insider activity, last 90 days

Net open-market
$-0.58m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

During the second quarter of 2026, the Company received $14.5 million in refunds for previously paid IEEPA tariffs, which were recorded primarily as a reduction to cost of product revenues. Additionally, we provide pharmacy services to individuals with intellectual and developmental disabilities (“IDD”), a market currently experiencing rising demand due to increased prevalence. Total U.S. prescription dispensing revenues across retail, mail-order, long-term care, and specialty pharmacies reached approximately $683 billion in 2024, up 9% from 2023, a surge driven primarily by the rapid adoption of GLP-1 agonists and specialty immunotherapies rather than volume alone. …OMNICELL, INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →